Drug Trial Radar · NCT01660620
Topical Betaxolol for the Prevention of Retinopathy of Prematurity
Last checked: Nov 20, 2026Latest source record: Jan 3, 2013 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
23
Actual
Start
Apr 2011
Primary completion
Nov 2011
Study completion Nov 2011
Sponsor
- Lead sponsor
- Smith-Kettlewell Eye Research InstituteAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Ohio State University; University of Minnesota; University of Oklahoma; The University of Texas Health Science Center, Houston
- First posted
- Aug 8, 2012
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- Who can join
- All sexes, from 32 weeks, up to 32 weeks
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
We hypothesize that topical betaxolol will reduce the development of severe retinopathy of prematurity.
Conditions
- Development of Side Effects From Betaxolol
Interventions
BetaxololDrug
topical betaxololDrug
given topically
Primary outcomes
What the sponsor says the trial is designed to measure.
- development of apnea and or bradycardiaTime frame: 3 weeks
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.